SCHEMBL2478657

SCHEMBL2478657

NNC(=O)[C@H]1CC[C@H](Oc2ccc3ccccc3c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 8/20 0.52
L3MBTL1 Q9Y468 1/20 0.47
GSK3B P49841 1/20 0.44
ACSL1 P33121 3/20 0.43
FAAH O00519 1/20 0.43
EPHX1 P07099 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
ACSL3 O95573 1/20 0.42
ACSL6 Q9UKU0 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2478658 1.00 ABL1 (0.52) ABL1L3MBTL1GSK3BACSL1FAAH
SCHEMBL2475966 0.84 GAA (0.47) ACSL1FAAHRAB9ANPC1MAPT
SCHEMBL2476884 0.84 GAA (0.47) ACSL1FAAHRAB9ANPC1MAPT
SCHEMBL2475964 0.84 GAA (0.47) ACSL1FAAHRAB9ANPC1MAPT
SCHEMBL2474271 0.82 L3MBTL1 (0.55) ABL1L3MBTL1ACSL1FAAHEPHX1
SCHEMBL2474274 0.82 L3MBTL1 (0.55) ABL1L3MBTL1ACSL1FAAHEPHX1
SCHEMBL16902878 0.80 CYP1A2 (0.50) L3MBTL1FAAHEPHX1HPGDHTT
SCHEMBL30477858 0.80 CYP1A2 (0.50) L3MBTL1FAAHEPHX1HPGDHTT
SCHEMBL2472723 0.80 MTNR1A (0.54) RAB9ANPC1MAPT
SCHEMBL2472720 0.80 MTNR1A (0.54) RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370441-B1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-09-11 EP disclosed
US-8461152-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2013-06-11 US disclosed
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES SCHNIDER PATRICK (CH) 2012-09-06 US disclosed
US-8227458-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
EP-2370441-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-10-05 EP disclosed
WO-2010060836-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-03 WO disclosed
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES HOFFMANN-LA ROCHE, INC. 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 ABL1 1633/4885L3MBTL1 3986/4885GSK3B 4332/4885
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 ABL1 1633/4885L3MBTL1 3986/4885GSK3B 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.